A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts. METHODS: We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival. RESULTS: After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft-allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43% vs. 7%, P<0.001). The cumulative incidence rates of grades II, III, and IV graft-versus-host disease (GVHD) combined and of grade IV GVHD in the autograft-allograft group were 43% and 4%, respectively. Overall, 21 of 58 patients (36%) were in complete remission after a median follow-up of 38 months (range, 10 to 72) after allografting. Of the 46 patients who received two autografts, 25 (54%) died. CONCLUSIONS: Among patients with newly diagnosed myeloma, survival in recipients of a hematopoietic stem-cell autograft followed by a stem-cell allograft from an HLA-identical sibling is superior to that in recipients of tandem stem-cell autografts. (ClinicalTrials.gov number, NCT00415987 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The role of allogeneic and non-myeloablative-allogeneic transplantation in multiple myeloma is controversial with studies showing conflicting results.138–140”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [139]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationGooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Research works printed but not linked: 1
- Sullivan KM, 1991, Semin Hematol, 28, 250
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationLuznik, L., O'Donnell, P. V., Symons, H. J., Chen, A. R., Leffell, M. S., Zahurak, M., Gooley, T. A., Piantadosi, S., Kaup, M., Ambinder, R. F., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.03.005 · Cited by 1,938
“The incidence of GVHD in our study is similar to that reported with reduced intensity HLAmatched sibling and unrelated donor transplantation [37-40].”
ResultSelf-citationKyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 855
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
“The role of allogeneic and non-myeloablative-allogeneic transplantation in multiple myeloma is controversial, with studies showing conflicting results.(126,127) The treatment-related mortality (TRM) rate (10%–20%) and GVHD rates are fairly high.”
ResultMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
“The role of allogeneic and non-myeloablative-allogeneic transplantation in multiple myeloma is controversial with studies showing conflicting results.(122,123) The treatment related mortality (TRM) rate (10%-20%) and GVHD rates are fairly high.”
BackgroundMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
“Data from randomized trials regarding the benefit of allogeneic ASCT are conflicting.(88,89) Even with a tandem approach of ASCT followed by an HLAidentical sibling donor mini-allogeneic transplant, the TRM is high at approximately 10% to 15%.”
BackgroundKumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 456
Snowden, J. A., Sánchez-Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Camara, R., Dolstra, H., Duarte, R. F., Glass, B., Greco, R., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01691-w · Cited by 379
Ljungman, P., Bregni, M., Brune, M., Cornelissen, J., Witte, T. D., Dini, G., Einsele, H., Gaspar, H. B., Gratwohl, A., Passweg, J., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.141 · Cited by 388
Casucci, M., Nicolis di Robilant, B., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., et al. (2013) · Blood · doi:10.1182/blood-2013-04-493361 · Cited by 357
for the European Society for Blood and Marrow Transplantation (EBMT), Duarte, R. F., Labopin, M., Bader, P., Basak, G. W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0516-2 · Cited by 337
Rajkumar, S. V., Rosiñol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 343
Sureda, A., Bader, P., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., Falkenburg, J. H. F., Farge-Bancel, D., Gennery, A., Kröger, N., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.6 · Cited by 337
Guidelines for the diagnosis and management of multiple myeloma 2011
Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08573.x · Cited by 306
“Several ‘biological’ (donor versus no donor) studies have been reported (Garban et al, 2006; Bruno et al, 2007; Rosiñol et al, 2008), summarized in Appendix III, Table 7.”
BackgroundRajkumar, S. V. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.63 · Cited by 289
“Bruno and colleagues found a significant overall survival advantage with ASCT followed by non-myeloablative allograft compared with tandem ASCT”
BackgroundMultiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0023 · Cited by 279
Krishnan, A., Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70243-1 · Cited by 274
Ladetto, M., Pagliano, G., Ferrero, S., Cavallo, F., Drandi, D., Santo, L., Crippa, C., De Rosa, L., Pregno, P., Grasso, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7172 · Cited by 267
Self-citationRosiñol, L., Pérez-Simón, J. A., Sureda, A., de la Rubia, J., de Arriba, F., Lahuerta, J. J., González, J. D., Díaz-Mediavilla, J., Hernández, B., García-Frade, J., et al. (2008) · Blood · doi:10.1182/blood-2008-02-141598 · Cited by 264
Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group
Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., et al. (2016) · Leukemia · doi:10.1038/leu.2015.356 · Cited by 258
Self-citationGiralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., Kumar, S., Munshi, N. C., Dispenzieri, A., Kyle, R., et al. (2009) · Leukemia · doi:10.1038/leu.2009.127 · Cited by 231
Self-citationMultiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 209
“The role of allogeneic and nonmyeloablative-allogeneic transplantation in multiple myeloma is controversial with studies showing conflicting results.(118,119) The treatment related mortality (TRM) rate (10%-20%) and GVHD rates are fairly high.”
BackgroundAnderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Cohen, A. D., Devine, S., Djulbegovic, B., Gasparetto, C., Huff, C. A., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0061 · Cited by 226
Allogeneic hematopoietic cell transplantation: the state of the art
Gyurkocza, B., Rezvani, A., & Storb, R. F. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.21 · Cited by 202
Self-citationRosenblatt, J., Avivi, I., Vasir, B., Uhl, L., Munshi, N. C., Katz, T., Dey, B. R., Somaiya, P., Mills, H., Campigotto, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0282 · Cited by 206
Kneppers, E., van der Holt, B., Kersten, M.-J., Zweegman, S., Meijer, E., Huls, G., Cornelissen, J. J., Janssen, J. J., Huisman, C., Cornelisse, P. B., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348292 · Cited by 193
Gahrton, G., Iacobelli, S., Björkstrand, B., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Carella, A. M., Beksac, M., et al. (2013) · Blood · doi:10.1182/blood-2012-11-469452 · Cited by 191
Björkstrand, B., Iacobelli, S., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Musto, P., Beksac, M., Bosi, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7312 · Cited by 182
Kidney Disease and Multiple Myeloma
Heher, E. C., Rennke, H. G., Laubach, J. P., & Richardson, P. G. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12231212 · Cited by 169
Lokhorst, H., Einsele, H., Vesole, D., Bruno, B., Miguel, J. S., Pérez-Simon, J. A., Kröger, N., Moreau, P., Gahrton, G., Gasparetto, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7929 · Cited by 161
“This is illustrated by the improved response to DLI by thalidomide apparently without enhancing GVHD.74 Impressive results were obtained with lenalidomide as salvage therapy in a group of patients with progressive symptomatic disease after Allo-RIC.75,76 Bortezomib has also been shown to be remarkably effective in pat…”
ResultSelf-citationTreatment of Multiple Myeloma: A Comprehensive Review
Kyle, R. A., & Rajkumar, S. V. (2009) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2009.n.056 · Cited by 151
The allogeneic graft‐versus‐cancer effect
Ringdén, O., Karlsson, H., Olsson, R., Omazic, B., & Uhlin, M. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07886.x · Cited by 155
“One randomized study showed that this approach was not better than two proceeding autografts (Garban et al, 2006), while another study showed a survival advantage with autografting followed by NMC allogeneic HSCT compared to double autografting (Bruno et al, 2007).”
ResultApproach to the treatment of multiple myeloma: a clash of philosophies
Rajkumar, S. V., Gahrton, G., & Bergsagel, P. L. (2011) · Blood · doi:10.1182/blood-2011-06-297853 · Cited by 137
How I treat multiple myeloma in younger patients
Stewart, A. K., Richardson, P. G., & San-Miguel, J. F. (2009) · Blood · doi:10.1182/blood-2009-07-204651 · Cited by 133
Hematopoietic stem cell transplantation for multiple myeloma beyond 2010
Bladé, J., Rosiñol, L., Cibeira, M. T., Rovira, M., & Carreras, E. (2010) · Blood · doi:10.1182/blood-2009-08-238196 · Cited by 138
“In contrast, the Italian group (99) found an increased CR rate and a significant survival advantage in favor of Allo-RIC, along with a survival plateau beyond 4 years from allografting.”
BackgroundResultHaynes, R., Read, S., Collins, G. P., Darby, S. C., & Winearls, C. G. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp488 · Cited by 129
Shah, N., Callander, N. S., Ganguly, S., Gul, Z., Hamadani, M., Costa, L. J., Sengsayadeth, S. M., Abidi, M. H., Hari, P., Mohty, M., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.03.002 · Cited by 140
“The 2 trials with the longest duration of follow up [115,116,119,120] (96 and 86 months) are also the only trials reporting superior PFS and OS among patients assigned to auto-HCT-allo-HCT.”
BackgroundInfluentialGay, F., Engelhardt, M. M., Terpos, E., Wäsch, R., Giaccone, L., Auner, H. W., Caers, J., Gramatzki, M., van de Donk, N. W. C. J., Oliva, S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.174573 · Cited by 133
Self-citationCase volume and mortality in haematological patients with acute respiratory failure
Lécuyer, L., Chevret, S., Guidet, B., Aegerter, P., Martel, P., Schlemmer, B., & Azoulay, É. (2008) · European Respiratory Journal · doi:10.1183/09031936.00142907 · Cited by 129
Giaccone, L., Storer, B. E., Patriarca, F. F., Rotta, M., Sorasio, R., Allione, B., Carnevale‐Schianca, F., Festuccia, M. B., Brunello, L., Omedè, P., et al. (2011) · Blood · doi:10.1182/blood-2011-03-339945 · Cited by 129
“A first report of this trial was previously published.(12) For personal use only.”
InfluentialSelf-citationFifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation
Bayraktar, U. D., Bashir, Q., Qazilbash, M., Champlin, R. E., & Ciurea, S. O. (2013) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2012.08.011 · Cited by 119
“Overall, two randomized trials have shown that ASCT followed by RIC allo-SCT leads to superior PFS and OS(77, 80) and one randomized trial has shown a trend towards superior PFS with this approach(76).”
BackgroundSensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis
Stern, M., de Wreede, L. C., Brand, R., van Biezen, A., Dreger, P., Mohty, M., de Witte, T. M., Kröger, N. M., Ruutu, T., & for the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (2014) · Leukemia · doi:10.1038/leu.2014.145 · Cited by 120
Peinert, S., Prince, H. M., Guru, P., Kershaw, M. H., Smyth, M. J., Trapani, J. A., Gambell, P. C., Harrison, S. J., Scott, A. M., Smyth, F. E., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.21 · Cited by 118
Moreau, P., Garban, F., Attal, M., Michallet, M., Marit, G., Hulin, C., Benboubker, L., Doyen, C., Mohty, M., Yakoub‐Agha, I., et al. (2008) · Blood · doi:10.1182/blood-2008-07-168823 · Cited by 115
Lokhorst, H. M., van der Holt, B., Cornelissen, J. J., Kersten, M. J., van Oers, M. H. J., Raymakers, R. A. P., Minnema, M. C., Zweegman, S., Janssen, J. J. W. M., Zijlmans, M., et al. (2012) · Blood · doi:10.1182/blood-2011-11-393801 · Cited by 104
Lioznov, M. V., Cheikh, J. E., Hoffmann, F. A., Hildebrandt, Y., Ayuk, F. A., Wolschke, C., Atanackovic, D., Schilling, G., Badbaran, A., Bacher, U., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.155 · Cited by 104
Rotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., Lange, T., Agura, E. D., McSweeney, P. A., Pulsipher, M. A., Hari, P., et al. (2008) · Blood · doi:10.1182/blood-2008-07-170746 · Cited by 108
“VGPR 19 CR 6 CR 6 2 (25, 77) 2 (3, 7) 2 (55, 89) VGPR 13 CR 13 6 (median 26, range 16-38) 1 (47) 6 (median 47, range 30-83) PR 50 CR 4 CR 4 2 (11, 11) 2 (47, 85) VGPR 10 CR 6 2 (14, 16) 4 (median 81, range 35-102) VGPR 4 2 (56, 66) 2 (5,77) PR 36 PR 14 7 (median 17, range 1-48) 5 (median 7, range 3-13) 2 (33, 49) VGPR…”
Self-citationEuropean Perspective on Multiple Myeloma Treatment Strategies in 2014
Ludwig, H., Sonneveld, P., Davies, F., Bladé, J., Boccadoro, M., Cavo, M., Morgan, G., de la Rubia, J., Delforge, M., Dimopoulos, M., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0042 · Cited by 99
Self-citationMultiple Myeloma: Charging Toward a Bright Future
Katzel, J. A., Hari, P., & Vesole, D. H. (2007) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.57.5.301 · Cited by 121
Alsina, M., Becker, P. S., Zhong, X., Adams, A. J., Hari, P., Rowley, S. D., Stadtmauer, E. A., Vesole, D. H., Logan, B. R., Weisdorf, D. J., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.04.014 · Cited by 105
“Although the role of alloHCT in MM remains controversial, several studies have shown encouraging PFS and OS with this treatment modality with prolonged follow-up and even in patients with high-risk disease [16,17].”
BackgroundImpact of early relapse after auto-SCT for multiple myeloma
Kumar, S. K., Mahmood, S., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Dingli, D., Rajkumar, S. V., Litzow, M. R., & Gertz, M. A. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.180 · Cited by 102
Uses and Growth of Hematopoietic Cell Transplantation
Horowitz, M. M. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch2 · Cited by 101
Bruno, B., Rotta, M., Patriarca, F. F., Mattei, D. G., Allione, B., Carnevale‐Schianca, F., Sorasio, R., Rambaldi, A., Casini, M., Parma, M., et al. (2008) · Blood · doi:10.1182/blood-2008-07-167379 · Cited by 100
“Albumin 3.5 g/dL 21/95 (22) 21/92 (23) Creatinine 2 mg/dL 11 (11) 11 (11) LDH above normal level 17/91 (19) 16/88 (18) Presence of chromosome 13 deletion 14/43 (33) 13/39 (33) HCT-specific comorbidity index 3 11 (11) 10 ( 10 )”
InfluentialSelf-citationWolschke, C., Stübig, T., Hegenbart, U., Schönland, S. O., Heinzelmann, M., Hildebrandt, Y., Ayuk, F. A., Atanackovic, D., Dreger, P., Zander, A. R., et al. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.10.004 · Cited by 94
Fionda, C., Soriani, A., Malgarini, G., Iannitto, M. L., Santoni, A., & Cippitelli, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901797 · Cited by 93
Principles and Overview of Allogeneic Hematopoietic Stem Cell Transplantation
Giralt, S., & Bishop, M. R. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-78580-6_1 · Cited by 95
“Results of a prospective biologically assigned study suggest, however, that the use of nonmyeloablative allogeneic HSCT may be superior to autologous HSCT in newly diagnosed myeloma patients [102].”
BackgroundKröger, N. M., Badbaran, A., Zabelina, T., Ayuk, F. A., Wolschke, C., Alchalby, H., Klyuchnikov, E., Atanackovic, D., Schilling, G., Hansen, T., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.10.008 · Cited by 94
“Some randomized studies using an autoeallo tandem SCT approach have suggested a benefit for OS [9-13,28].”
BackgroundKröger, N. M., Badbaran, A., Lioznov, M. V., Schwarz, S., Zeschke, S., Hildebrand, Y., Ayuk, F. A., Atanackovic, D., Schilling, G., Zabelina, T., et al. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.03.008 · Cited by 88
“The CR rate of allogeneic stem cell transplantation after standard myeloablative and dose-reduced conditioning ranged between 27% and 81% [3–9].”
BackgroundIndividualizing Treatment of Patients With Myeloma in the Era of Novel Agents
Miguel, J. F. S., Harousseau, J., Joshua, D., & Anderson, K. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2546 · Cited by 90
Can multiple myeloma become a curable disease?
Miguel, J. F. S., & Mateos, M. ‐. (2011) · Haematologica · doi:10.3324/haematol.2011.051169 · Cited by 89
“However, its high transplant-related mortality, the advanced age of patients, and donor limitations restrict this treatment to a small number of patients, and remains an investigative approach.(2,6,7) With HDT/ASCT, 3-10% of MM patients will remain in complete remission for more than ten years and can be considered “o…”
BackgroundPatriarca, F. F., Einsele, H., Spina, F., Bruno, B., Isola, M., Nozzoli, C., Nozza, A., Sperotto, A. A., Morabito, F., Stuhler, G., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.07.026 · Cited by 84
“Several randomized trials of auto-SCT with or without NMA allo-SCT from HLA-identical sibling donors in newly diagnosed patients have been conducted 11, 12, 13, 14, and superior event-free survival and OS in the allo-SCT arm have been suggested in 2 of these studies 12, 13.”
Self-citationSchilling, G., Hansen, T., Shimoni, A., Zabelina, T., Simon-Perez, J.-A., Gutierrez, N. C., Bethge, W. A., Liebisch, P., Schwerdtfeger, R., Bornhäuser, M., et al. (2008) · Leukemia · doi:10.1038/leu.2008.88 · Cited by 79
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis
Kumar, S. K., Zhang, M., Li, P., Dispenzieri, A. A., Milone, G., Lonial, S., Krishnan, A. Y., Maiolino, Â., Wirk, B. M., Weiss, B. M., et al. (2011) · Blood · doi:10.1182/blood-2011-02-337329 · Cited by 77
“001 Time from auto-HCT to allo-HCT, mo Median (range) 11 (3-31) 16 (2-77) 6 (1-89) .”
InfluentialGratwohl, A. A., Baldomero, H., Frauendorfer, K., Rocha, V., Apperley, J. F., & Niederwieser, D. W. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705956 · Cited by 77
Greil, C., Engelhardt, M. M., Ihorst, G., Schoeller, K., Bertz, H., Marks, R., Zeiser, R., Duyster, J., Einsele, H., Finke, J., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.200881 · Cited by 77
Treatment of Myeloma: Cure vs Control
Rajkumar, S. V. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.10.1142 · Cited by 73
Multiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C. L., Djulbegović, B., Fung, H. C. H., Gasparetto, C., Godby, K. N., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0167 · Cited by 85
Armeson, K. E., Hill, E. G., & Costa, L. J. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.173 · Cited by 74
Rajkumar, S. V. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.01.001 · Cited by 94
Swift, B. E., Williams, B. A., Kosaka, Y., Wang, X.-H., Medin, J. A., Viswanathan, S., Martínez‐López, J., & Keating, A. (2012) · Haematologica · doi:10.3324/haematol.2011.054254 · Cited by 74
Greco, R., Ruggeri, A., McLornan, D. P., Snowden, J. A., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A. A., Hazenberg, M. D., Kałwak, K., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02701-3 · Cited by 78
“The combination of auto-HCT followed by RIC allograft ( ‘ auto-allo ’ ) has shown a survival bene fi t in selected high-risk patients, albeit inconsistently in various clinical trials [187 – 190].”
Fionda, C., Malgarini, G., Soriani, A., Zingoni, A., Cecere, F., Iannitto, M. L., Ricciardi, M. R., Federico, V., Petrucci, M. T., Santoni, A., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201426 · Cited by 79
“fect mediated by donor lymphocytes (10, 11).”
Bonanno, G., Mariotti, A., Procoli, A., Folgiero, V., Natale, D., De Rosa, L., Majolino, I., Novarese, L., Rocci, A., Gambella, M., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-247 · Cited by 67
“None Alive/MGUS 13 MM Onset Micromolecular, κ Normal III Auto-HSCT Alive/CR 14 MM Relapse IgA κ Del(13q) I Prednisone Alive/PD 15 MM Onset NA Normal II None NA 16 MM Partial response IgG λ Normal III PDN Alive/Stable disease 17 MM Relapse IgA λ Normal III PDN Alive/PR 18 SMM Onset IgA κ Normal N.A.”
InfluentialSelf-citationSobh, M. A. K., Michallet, M., Gahrton, G., Iacobelli, S., van Biezen, A., Schönland, S. O., Petersen, E. J., Schaap, N. P., Bonifazi, F., Volin, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.101 · Cited by 71
Self-citationReduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
de Lavallade, H., Cheikh, J. E., Faucher, C., Fürst, S., Am, S., Coso, D., Bouabdallah, R., Chabannon, C., Gastaut, J. A., Blaise, D., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.22 · Cited by 69
Immunotherapy in myeloma: how far have we come?
Franssen, L. E., Mutis, T., Lokhorst, H. M., & van de Donk, N. W. C. J. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718822660 · Cited by 66
Atanackovic, D., Cao, Y., Luetkens, T., Panse, J., Faltz, C., Arfsten, J., Bartels, K., Wolschke, C., EIERMANN, T. H., Zander, A. R., et al. (2008) · Haematologica · doi:10.3324/haematol.11897 · Cited by 63
“Following allogeneic SCT lower relapse rates have been reported, probably due to a graft-versus-myeloma effect mediated by donor lymphocytes.(2) A proportion of patients treated with allogeneic SCT even achieve molecular remission resulting in long-term freedom of disease.”
BackgroundInfluentialKidney disease associated with plasma cell dyscrasias
Heher, E. C., Goes, N. B., Spitzer, T. R., Raje, N. S., Humphreys, B. D., Anderson, K. C., & Richardson, P. G. G. (2010) · Blood · doi:10.1182/blood-2010-03-258608 · Cited by 63
Cheikh, J. E., Michallet, M., Nagler, A., de Lavallade, H., Nicolini, F. E., Shimoni, A., Faucher, C., Sobh, M. A. K., Revesz, D., Hardan, I., et al. (2008) · Haematologica · doi:10.3324/haematol.12184 · Cited by 62
The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies
Hoyos, V., & Borrello, I. (2016) · Blood · doi:10.1182/blood-2016-05-636357 · Cited by 64
Sive, J. I., Cuthill, K., Hunter, H. M., Kazmi, M. A., Pratt, G., Smith, D., & British Society of Haematology (2021) · British Journal of Haematology · doi:10.1111/bjh.17410 · Cited by 69
Passweg, J. R., Halter, J. P., Bucher, C., Gerull, S., Heim, D. A., Rovó, A., Buser, A. S., Stern, M., & Tichelli, A. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13696 · Cited by 85
Somlo, G., Spielberger, R. T., Frankel, P. H., Karanes, C., Krishnan, A. Y., Parker, P. M., Popplewell, L. L., Sahebi, F., Kogut, N. M., Snyder, D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1912 · Cited by 64
“5) 5 (23) 11 (50) 6 (27) 12 (55) 6 (27) 4 (18)”
Allogeneic stem cell transplantation for multiple myeloma: is there a future?
Dhakal, B., Vesole, D. H., & Hari, P. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.325 · Cited by 64
Bone marrow transplantation generates T cell–dependent control of myeloma in mice
Vučković, S., Minnie, S. A., Smith, D. D., Gartlan, K. H., Watkins, T. S., Markey, K. A., Mukhopadhyay, P., Guillerey, C., Kuns, R. D., Locke, K. R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98888 · Cited by 63
“It is generally presumed that the therapeutic benefit of myeloablative chemotherapy and autologous SCT is a result of intensive cytoreduction (7).”
BackgroundInfluentialRole of autologous and allogeneic stem cell transplantation in myeloma
Bensinger, W. (2009) · Leukemia · doi:10.1038/leu.2008.396 · Cited by 65
Emerging therapies for multiple myeloma
Podar, K., Tai, Y., Hideshima, T., Vallet, S., Richardson, P. G. G., & Anderson, K. C. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802676278 · Cited by 62
“Of note, autologous SCT followed by allografting with nonmyeloablative conditioning achieved dramatic reduction of transplant-related mortality with potent antitumor activity [50,51] .”
ResultInfluentialIndividual Physician Practice Variation in Hematopoietic Cell Transplantation
Lee, S. J., Joffe, S., Artz, A. S., Champlin, R. E., Davies, S. M., Jagasia, M., Kernan, N. A., Loberiza, F. R., Soiffer, R. J., & Eapen, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0169 · Cited by 64
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
Bensinger, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6863 · Cited by 61
Donato, M. L., Siegel, D. S. D., Vesole, D. H., McKiernan, P., Nyirenda, T. L., Pecora, A. L., Baker, M., Goldberg, S. L., Mato, A. R., Goy, A. H., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.04.027 · Cited by 56
“The Italian trial showed improvement in PFS and OS for the autologousallogeneic group [18].”
BackgroundInfections in Patients With Multiple Myeloma
Nucci, M., & Anaissie, E. J. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.03.006 · Cited by 56
Roos‐Weil, D., Moreau, P., Avet‐Loiseau, H., Golmard, J., Kuentz, M., Vigouroux, S., Socié, G., Fürst, S., Soulier, J., Gouill, S. L., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.042713 · Cited by 56
“The data suggest that allo-SCT can overcome the negative impact of t(4;14) but does not benefit del(17p) patients who still have poor outcomes.”
BackgroundInfluentialThe future of autologous stem cell transplantation in myeloma
van Rhee, F., Giralt, S., & Barlogie, B. (2014) · Blood · doi:10.1182/blood-2014-03-561985 · Cited by 53
“The results with autotransplant followed by miniallogeneic transplant have been mixed, but in 2 studies the benefit in terms of PFS andOSwas noted attesting to the potential for exploiting the immune system.(49,50) Presently, allogeneic transplant for myeloma should be only performed in the context of a clinical trial.”
Engelhardt, M. M., Kleber, M., Udi, J., Wäsch, R., Spencer, A. G., Patriarca, F. F., Knop, S. T., Bruno, B., Gramatzki, M., Morabito, F., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.487959 · Cited by 56
“Despite treatment intensification, MM relapse usually occurs after ASCT and allo-SCT [1,3, 16,17], presumably because all patients harbor a proportion of MM cells with an anti-apoptotic phenotype conferring a high level of drug resistance.”
BackgroundResultInfluentialSelf-citationKharfan‐Dabaja, M. A., Hamadani, M., Reljic, T., Nishihori, T., Bensinger, W., Djulbegović, B., & Kumar, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-2 · Cited by 50
“patients were offered a dose of melphalan ranging from 100 to 200 mg/m(2) [15], whereas Rosiñol et al.”
BackgroundMethodResultInfluentialJahnke, A., Jahnke, L., Molina-Duran, F., Ehmann, M., Kantz, S., Steil, V., Wenz, F. K., Glatting, G., Lohr, F., & Poledník, M. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.12.009 · Cited by 46
“The purpose of conditioning is to suppress the immune system to allow engraftment of donor cells, to kill malignant cells and to eradicate cell populations with genetic disorders [1,2].”
BackgroundAllogeneic Stem Cell Transplantation for Multiple Myeloma
Bensinger, W. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.001 · Cited by 46
Cheikh, J. E., Crocchiolo, R., Fürst, S., Ladaique, P., Castagna, L., Faucher, C., Granata, A., Oudin, C., Lemarié, C., Calmels, B., et al. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.02.009 · Cited by 46
Metadata
- Authors
- Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., Bringhen, S., Massaia, M., Aglietta, M., Levis, A., Gallamini, A., Fanin, R., Palumbo, A., Storb, R., Ciccone, G., & Boccadoro, M.
- Affiliations
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- University of Udine (IT)
- Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT)
- Candiolo Cancer Institute (IT)
- University of Washington (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-03-15
- Volume
- 356
- Issue
- 11
- Pages
- 1110-1120
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2010766702
- Semantic Scholar
- 67383c7f6bdb3318b2667d1aad826b28d4117193
- Cited by
- 501
- References
- 35
- Citations by year
- 2025: 3 · 2024: 8 · 2023: 11 · 2022: 10 · 2021: 14 · 2020: 16 · 2019: 13 · 2018: 16 · 2017: 26 · 2016: 22 · 2015: 34 · 2014: 23 · 2013: 43 · 2012: 33
- FWCI
- 40.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- National Cancer Institute (CA 78902, P01CA078902)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, allogeneic stem cell transplantation, autologous stem cell transplantation, matched sibling donor, graft-versus-host disease, overall survival, event-free survival, complete remission, non-relapse mortality, newly diagnosed multiple myeloma
- MeSH terms
- Adult, Aged, Female, Follow-Up Studies, Graft vs Host Disease, Histocompatibility Testing, Humans, Male, Middle Aged, Multiple Myeloma, Transplantation, Autologous, Transplantation, Homologous, Multivariate Analysis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Siblings
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.